Our Company
Presentation
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
OSE-127/Lusvertikimab
FR104/VEL-101
BI 765063
BI 770371
OSE-230
CLEC-1
BiCKI®
Research & Development
Scientific publications
Investors
Press Releases
Regulated information
Financial documents
General Shareholders’ meetings
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Agenda
Press Releases
Contact
en
fr
Retour aux communiqués
Date
OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update
Téléchargez